Moderna short sellers face $4.8 billion loss amid record stock jump

Moderna shares have doubled following the release of cancer vaccine data, which has significantly rekindled investor confidence. This record stock jump has resulted in a massive financial blow for short sellers, who are now facing an estimated $4.8 billion loss. The surge in share price is directly attributed to the positive data regarding the company's vaccine developments, leading to one of the most substantial one-day losses for those betting against the stock.